Oral News and Research

RSS

Racial disparities in risk and survival among children with neuroblastoma: Study

Black, Asian, and Native American children are more likely than white and Hispanic children to die after being treated for neuroblastoma, according to new research on the pediatric cancer. The study, of more than 3,500 patients with the disease, is the largest ever to look at racial disparities in risk and survival for the most common solid cancer found in young children.

23 Nov 2010

AADR Fall Focused Symposium highlights fast-moving field of Salivary Diagnostics

The American Association for Dental Research (AADR) held its 3rd Fall Focused Symposium on November 12-13, in the Washington, DC, area. This year, the theme was the fast-moving field of Salivary Diagnostics, with a focus on Scientific & Clinical Frontiers.

23 Nov 2010

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

23 Nov 2010

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).

23 Nov 2010

USPTO issues patent for neurotherapeutic pharmaceutical formulation

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.

23 Nov 2010

Impax initiates challenge of patents relating to WELCHOL

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc. in connection with its WELCHOL® (Colesevelam HCl) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet.

22 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

OraSure granted FDA approval for final phase studies of OraQuick Rapid HIV-1/2 Antibody Test

OraSure Technologies, Inc., the market leader in oral fluid diagnostics, today announced that the U.S. Food and Drug Administration ("FDA") has granted an investigational device exemption (IDE) for the Company to conduct the final phase of clinical testing for FDA approval of its OraQuick® Rapid HIV-1/2 Antibody Test for sale in the consumer or over-the-counter ("OTC") market.

22 Nov 2010

Racial and socioeconomic disparities exist in kidney transplantation

Research shows that people with low incomes are more likely to develop kidney failure and less likely to receive a living donor kidney transplant than people of other socioeconomic classes.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Presence of albumin in urine predicts cognitive decline: Study

A new study has found that low amounts of albumin in the urine, at levels not traditionally considered clinically significant, strongly predict faster cognitive decline in older women.

21 Nov 2010

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Potassium citrate effective for prevention and treatment of osteoporosis: Study

The Western diet creates an acidic environment in the body that removes calcium from bones and may contribute to the development of osteoporosis. Healthy adults who consume the standard US diet sustain a chronic, low-grade state of acidosis that worsens with age as kidney function declines, limiting urinary acid excretion. Reto Krapf, MD (University of Basel, in Bruderholz/Basel, Switzerland) and colleagues designed a study to see if daily alkali as potassium citrate supplement tablets might neutralize these effects.

20 Nov 2010

HRSA awards $8 million for Community Health Center Cooperative Agreements

The Health Resources and Services Administration (HRSA) at the Department of Health and Human Services (HHS) today announced the awarding of nearly $8 million for existing Community Health Center Cooperative Agreements.

20 Nov 2010

New initiative to help improve oral health for North Carolina children

The North Carolina Head Start-State Collaboration Office and the American Academy of Pediatric Dentistry (AAPD), today announced the launch of the Head Start Dental Home Initiative to improve oral health for North Carolina children.

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

News outlets covered a range of developments including workforce issues in Minnesota and California, and a Kentucky order for insurers to provide child-only policies.

19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Oral News and Research

Racial disparities in risk and survival among children with neuroblastoma: Study

AADR Fall Focused Symposium highlights fast-moving field of Salivary Diagnostics

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

USPTO issues patent for neurotherapeutic pharmaceutical formulation

Impax initiates challenge of patents relating to WELCHOL

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

OraSure granted FDA approval for final phase studies of OraQuick Rapid HIV-1/2 Antibody Test

Racial and socioeconomic disparities exist in kidney transplantation

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Presence of albumin in urine predicts cognitive decline: Study

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Potassium citrate effective for prevention and treatment of osteoporosis: Study

HRSA awards $8 million for Community Health Center Cooperative Agreements

New initiative to help improve oral health for North Carolina children

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

NexACT technology improves oral delivery of five small molecule drugs

State roundup: California PPOs 'low marks'; Geriatric nursing; Physician shortages

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News